Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
(2016) In The Lancet Oncology 17(1). p.78-89- Abstract
- Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral triple angiokinase inhibitor of VEGF receptor, platelet-derived growth factor receptor, and fibroblast growth factor receptor, has shown activity in phase 2 trials in this setting. We investigated the combination of nintedanib with standard carboplatin and paclitaxel chemotherapy in patients with newly diagnosed advanced ovarian cancer.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8234927
- author
- Bois, Andreas du
; Kristensen, Gunnar
; Ray-Coquard, Isabelle
; Reuss, Alexander
; Pignata, Sandro
; Colombo, Nicoletta
; Denison, Ursula
; Vergote, Ignace
; Del Campo, Jose M
; Ottevanger, Petronella
; Heubner, Martin
; Minarik, Thomas
; Sevin, Emmanuel
; de Gregorio, Nikolaus
; Bidziński, Mariusz
; Pfisterer, Jacobus
; Malander, Susanne
LU
; Hilpert, Felix
; Mirza, Mansoor R
; Scambia, Giovanni
; Meier, Werner
; Nicoletto, Maria O
; Bjørge, Line
; Lortholary, Alain
; Sailer, Martin Oliver
; Merger, Michael
and Harter, Philipp
(Less) - organization
- publishing date
- 2016
- type
- Contribution to journal
- publication status
- published
- subject
- in
- The Lancet Oncology
- volume
- 17
- issue
- 1
- pages
- 78 - 89
- publisher
- Elsevier
- external identifiers
-
- pmid:26590673
- wos:000367099700044
- scopus:84955299214
- ISSN
- 1474-5488
- DOI
- 10.1016/S1470-2045(15)00366-6
- language
- English
- LU publication?
- yes
- id
- 4fce8636-9eeb-4a2d-ba1c-c7143297e5b1 (old id 8234927)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26590673?dopt=Abstract
- date added to LUP
- 2016-04-01 10:47:59
- date last changed
- 2022-04-04 21:23:37
@article{4fce8636-9eeb-4a2d-ba1c-c7143297e5b1,
abstract = {{Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral triple angiokinase inhibitor of VEGF receptor, platelet-derived growth factor receptor, and fibroblast growth factor receptor, has shown activity in phase 2 trials in this setting. We investigated the combination of nintedanib with standard carboplatin and paclitaxel chemotherapy in patients with newly diagnosed advanced ovarian cancer.}},
author = {{Bois, Andreas du and Kristensen, Gunnar and Ray-Coquard, Isabelle and Reuss, Alexander and Pignata, Sandro and Colombo, Nicoletta and Denison, Ursula and Vergote, Ignace and Del Campo, Jose M and Ottevanger, Petronella and Heubner, Martin and Minarik, Thomas and Sevin, Emmanuel and de Gregorio, Nikolaus and Bidziński, Mariusz and Pfisterer, Jacobus and Malander, Susanne and Hilpert, Felix and Mirza, Mansoor R and Scambia, Giovanni and Meier, Werner and Nicoletto, Maria O and Bjørge, Line and Lortholary, Alain and Sailer, Martin Oliver and Merger, Michael and Harter, Philipp}},
issn = {{1474-5488}},
language = {{eng}},
number = {{1}},
pages = {{78--89}},
publisher = {{Elsevier}},
series = {{The Lancet Oncology}},
title = {{Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.}},
url = {{http://dx.doi.org/10.1016/S1470-2045(15)00366-6}},
doi = {{10.1016/S1470-2045(15)00366-6}},
volume = {{17}},
year = {{2016}},
}